<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>As key molecules that drive progression and chemoresistance in <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancers</z:e>, epidermal growth factor receptor (EGFR) and HER2 have become efficacious drug targets in this setting </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="49603">Lapatinib</z:chebi> is an EGFR/HER2 kinase inhibitor suppressing signaling through the <z:mp ids='MP_0011356'>RAS</z:mp>/RAF/MEK (MAP/ERK kinase)/MAPK (<z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase) and PI3K (<z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> 3-kinase)/AKT pathways </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="15358">Histone</z:chebi> deacetylase inhibitors (HDACi) are a novel class of agents that induce cell cycle arrest and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> following the acetylation of <z:chebi fb="0" ids="15358">histone</z:chebi> and nonhistone proteins modulating gene expression and disrupting HSP90 function inducing the degradation of EGFR-pathway client proteins </plain></SENT>
<SENT sid="3" pm="."><plain>This study sought to evaluate the therapeutic potential of combining <z:chebi fb="0" ids="49603">lapatinib</z:chebi> with the HDACi panobinostat in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cell lines with varying EGFR/HER2 expression and KRAS/BRAF/PIK3CA mutations </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="49603">Lapatinib</z:chebi> and panobinostat exerted concentration-dependent antiproliferative effects in vitro (panobinostat range 7.2-30 nmol/L; <z:chebi fb="0" ids="49603">lapatinib</z:chebi> range 7.6-25.8 μmol/L) </plain></SENT>
<SENT sid="5" pm="."><plain>Combined <z:chebi fb="0" ids="49603">lapatinib</z:chebi> and panobinostat treatment interacted synergistically to inhibit the proliferation and colony formation in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines tested </plain></SENT>
<SENT sid="6" pm="."><plain>Combination treatment resulted in rapid induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> that coincided with increased DNA double-strand breaks, caspase-8 activation, and PARP cleavage </plain></SENT>
<SENT sid="7" pm="."><plain>This was paralleled by decreased signaling through both the PI3K and MAPK pathways and increased downregulation of transcriptional targets including NF-κB1, IRAK1, and CCND1 </plain></SENT>
<SENT sid="8" pm="."><plain>Panobinostat treatment induced downregulation of EGFR, HER2, and HER3 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein through transcriptional and posttranslational mechanisms </plain></SENT>
<SENT sid="9" pm="."><plain>In the LoVo KRAS mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, the combination showed greater antitumor activity than either agent alone, with no apparent increase in toxicity </plain></SENT>
<SENT sid="10" pm="."><plain>Our results offer preclinical rationale warranting further clinical investigation combining HDACi with EGFR and HER2-targeted therapies for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> treatment </plain></SENT>
</text></document>